Phenyl-substituted nicotinic ligands, and methods of use thereof
Disclosed are compounds and methods of using them to treat a disorder selected from the group consisting of addiction, pain, obesity, schizophrenia, epilepsy, mania and manic depression, anxiety, Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Lewy Body Dementia, Attention Deficit Hyperactivity Disorder (ADHD), Parkinson's disease, Huntington's disease, Tourette's syndrome, amyotrophic lateral sclerosis, inflammation, stroke, spinal cord injury, dyskinesias, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, autism, mutism, trichotillomania, hypothermia, and disorders of sleep.
1. A compound of formula (I) or a pharmaceutically acceptable salt thereof
wherein:
R represents, independently for each occurrence, halogen, C1-C6 alkyl, allyl, C1-C6 alkyloxy, amino, hydroxyl, nitro, cyano, or trifluoro-C1-C4 alkyl;
R 1 represents hydrogen, C1-C6 alkyl, allyl, or C3-C6 cycloalkyl;
R 2 , R 3 , and R 4 independently represent hydrogen, C1-C6 alkyl, allyl, or C3-C6 cycloalkyl, or C1-C6 alkyl substituted with at least one fluorine;
m is 1;
n is an integer selected from 1 and 2; and
z is an integer ranging from 0 to 5.
2. The compound of claim 1 , wherein n is 1.
3. The compound of claim 1 , wherein z is 0 to 2.
4. The compound of claim 1 , wherein R represents, independently for each occurrence, halogen, C1-C6 alkyl, C1-C6 alkyloxy, amino, or trifluoro-C1-C4 alkyl.
5. The compound of claim 3 , wherein R represents, independently for each occurrence, halogen, methyl, methoxy, amino, or trifluoromethyl.
6. The compound of claim 1 , wherein R 1 is C1-C6 alkyl.
7. The compound of claim 1 , wherein R 1 is hydrogen.
8. The compound of claim 1 , wherein R 2 , R 3 , and R 4 independently represent hydrogen.
9. The compound of claim 8 , wherein the compound is
10. The compound of claim 1 , wherein the compound is selected from the group consisting of:
11. A pharmaceutical composition, comprising a compound of claim 1 ; and a pharmaceutically acceptable carrier.
12. The compound of claim 1 , wherein z is 0.
13. The compound of claim 1 , wherein z is 1.
14. The compound of claim 1 , wherein z is 2.
15. The compound of claim 6 , wherein R 1 is methyl.